Development and Validation of Amisulpride in Human Plasma by HPLC Coupled with Tandem Mass Spectrometry and its Application to a Pharmacokinetic Study
2011

Development and Validation of Amisulpride in Human Plasma

Sample size: 10 publication 10 minutes Evidence: high

Author Information

Author(s): Mogili Ramakotaiah, Kanala Kanchanamala, Challa Balasekhara Reddy, Chandu Babu Rao, Bannoth Chandrasekhar Kottapalli

Primary Institution: Jawaharlal Nehru Technological University, Anantapur, Andhra Pradesh, India

Hypothesis

To develop and validate a simple, sensitive, selective, fast, rugged and reproducible analytical method for quantification of Amisulpride in human plasma samples.

Conclusion

The developed method for quantifying Amisulpride in human plasma is fast, sensitive, and reproducible, making it suitable for pharmacokinetic studies.

Supporting Evidence

  • The method demonstrated intra- and inter-day precision within 0.9 to 1.7% and accuracy within 98.3 to 101.5%.
  • Amisulpride was stable through multiple freeze-thaw cycles and during storage.
  • The method was validated over a linear concentration range of 2.0–2500.0 ng/mL for Amisulpride.

Takeaway

Researchers created a new way to measure a medicine called Amisulpride in blood, which helps doctors understand how it works in people.

Methodology

The study used liquid chromatography-tandem mass spectrometry (LC-MS/MS) to quantify Amisulpride in human plasma, validated over a concentration range of 2.0–2500.0 ng/mL.

Limitations

The study may have limitations related to the specific population sample and the generalizability of the findings.

Participant Demographics

10 healthy human volunteers were included in the study.

Statistical Information

P-Value

p<0.05

Confidence Interval

90% CI within 80–125%

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3797/scipharm.1105-12

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication